MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1

Dong,Jing; Sui,Long; Wang,Qing; Chen,Mingjun; Sun,Hong

doi:10.3892/mmr.2014.2335

MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1

Authors:
- Jing Dong
- Long Sui
- Qing Wang
- Mingjun Chen
- Hong Sun
View Affiliations

Affiliations: Department of Gynecology, Obstetrics and Gynecology Hospital, Shanghai Medical College, Fudan University, Shanghai 200011, P.R. China
Published online on: June 16, 2014 https://doi.org/10.3892/mmr.2014.2335
Pages: 1426-1432

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The downregulation of microRNA‑26a (miR‑26a) has been reported in numerous types of cancer, but its detailed functional role in cervical cancer is not yet clear. In the present study, the expression of miR‑26a in human cervical cancer was confirmed and its contribution to cervical cancer progression was investigated. The expression of miR‑26a was determined by reverse transcription quantitative polymerase chain reaction in human cervical tissues and cell lines. Cell growth and invasion were detected by cell counting kit‑8, colony‑forming assays and transwell assays following restoration of miR‑26a expression. Protein tyrosine phosphatase type IVA 1 (PRL‑1) was further validated as a target of miR‑26a by a functional luciferase assay and western blot analysis. In addition, the overexpression of miR‑26a in tumor formation in SCID mice was investigated in vivo, and the association between miR‑26a and PRL‑1 was assayed by Pearson's correlation coefficient. First, it was identified that miR‑26a was significantly downregulated in cervical cancer compared with the paired adjacent tissues. Forced expression of miR‑26a suppressed cell proliferation and invasion in vitro and inhibited the growth of tumor xenografts in vivo. PRL‑1 was determined as a novel target for miR‑26a and knockdown of PRL‑1 partially phenocopied the effect of miR‑26a restoration. In addition, PRL‑1 expression was inversely correlated with miR‑26a expression in cervical cancer tissues. In conclusion, the results demonstrated the role of miR‑26a in cervical cancer pathogenesis and suggest it may be used as a potential novel therapeutic strategy for cervical cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
3	Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 137:516–542. 2012. View Article : Google Scholar
4	Farh KK, Grimson A, Jan C, et al: The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 310:1817–1821. 2005. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Marzi MJ, Puggioni EM, Dall’Olio V, et al: Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation. J Cell Biol. 199:77–95. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kane NM, Howard L, Descamps B, et al: Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells. 30:643–654. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zhu XC, Dong QZ, Zhang XF, et al: microRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma. Int J Mol Med. 30:1321–1326. 2012.PubMed/NCBI
9	Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
10	Lee JW, Choi CH, Choi JJ, et al: Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res. 14:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wang X, Tang S, Le SY, et al: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
12	Pereira PM, Marques JP, Soares AR, Carreto L and Santos MA: MicroRNA expression variability in human cervical tissues. PLoS One. 5:e117802010. View Article : Google Scholar : PubMed/NCBI
13	Gocze K, Gombos K, Juhasz K, et al: Unique microRNA expression profiles in cervical cancer. Anticancer Res. 33:2561–2567. 2013.PubMed/NCBI
14	Hirata H, Ueno K, Shahryari V, et al: Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One. 7:e510562012. View Article : Google Scholar : PubMed/NCBI
15	Xie H, Zhao Y, Caramuta S, Larsson C and Lui WO: miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One. 7:e469902012. View Article : Google Scholar : PubMed/NCBI
16	Wang X, Wang HK, McCoy JP, et al: Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA. 15:637–647. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wang F, Liu M, Li X and Tang H: MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. Febs Lett. 587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
18	Shen Y, Wang P, Li Y, et al: miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer. 109:92–99. 2013. View Article : Google Scholar : PubMed/NCBI
19	Dong J, Cheng M and Sun H: Function of inducible nitric oxide synthase in the regulation of cervical cancer cell proliferation and the expression of vascular endothelial growth factor. Mol Med Rep. 9:583–589. 2014.PubMed/NCBI
20	Fiordalisi JJ, Keller PJ and Cox AD: PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 66:3153–3161. 2006. View Article : Google Scholar : PubMed/NCBI
21	Bai Y, Luo Y, Liu S, et al: PRL-1 protein promotes ERK1/2 and RhoA protein activation through a non-canonical interaction with the Src homology 3 domain of p115 Rho GTPase-activating protein. J Biol Chem. 286:42316–42324. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chen HC, Chen GH, Chen YH, et al: MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
23	Lu J, He ML, Wang L, et al: MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 71:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
24	Yang X, Liang L, Zhang XF, et al: MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology. 58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhang B, Liu XX, He JR, et al: Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 32:2–9. 2011. View Article : Google Scholar : PubMed/NCBI
26	Huse JT, Brennan C, Hambardzumyan D, et al: The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 23:1327–1337. 2009. View Article : Google Scholar : PubMed/NCBI
27	Zhang J, Han C and Wu T: MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology. 143:246–256. 2012. View Article : Google Scholar : PubMed/NCBI
28	Liu B, Wu X, Liu B, et al: MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta. 1822:1692–1704. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kota J, Chivukula RR, O’Donnell KA, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
30	Lu JW, Chang JG, Yeh KT, et al: Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma. Clin Transl Oncol. 14:287–293. 2012. View Article : Google Scholar : PubMed/NCBI
31	Achiwa H and Lazo JS: PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res. 67:643–650. 2007. View Article : Google Scholar : PubMed/NCBI